Skip to main content
Premium Trial:

Request an Annual Quote

A New Team

Genentech and 23andMe are collaborating on a study to determine genetic influences on how breast cancer patients respond to bevacizumab, also known as Avastin, reports Erika Check Hayden at the Nature News blog. She adds that FDA recently revoked the approval for Avastin to be used to treat certain breast cancers. As our sister publication Pharmacogenomics Reporter noted at that time, Genentech said it was planning to conduct a clinical trial to find biomarkers that would identify breast cancer patients who would respond to the drug. Now, Genentech and 23andMe are recruiting people diagnosed with metastatic or recurrent breast cancer and who have been treated with bevacizumab for their new study. "23andMe has been increasingly turning towards research studies as consumer demand for its services has plateaued," Check Hayden adds.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.